secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001104659-24-062047
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode Therapeutics receives Nasdaq delisting notice; hearing set for June 25, 2024
--------------------------------------------------------------------------------

- Nasdaq delisting notice due to failure to maintain minimum $1.00 bid price for 30 consecutive business days.
- Company not eligible for second compliance period due to failure to meet $5M stockholders' equity requirement for initial listing.
- Appealed delisting on May 14, 2024; delisting stayed pending final written decision after hearing on June 25, 2024.
- Stock continues to trade on Nasdaq under symbol RNAZ; no assurance appeal will be successful.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924062047/0001104659-24-062047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924062047/tm2414638d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-062047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer